Splenic hyalohyphomycosis, molecularly and immunologically consistent with invasive aspergillosis, in a patient with acute lymphoblastic leukemia

Am J Hematol. 2010 Mar;85(3):188-9. doi: 10.1002/ajh.21438.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aspergillosis / drug therapy
  • Aspergillosis / etiology*
  • Aspergillosis / pathology
  • Aspergillosis / surgery
  • Aspergillus / isolation & purification*
  • Aspergillus / ultrastructure
  • Caspofungin
  • Combined Modality Therapy
  • Echinocandins / therapeutic use
  • Humans
  • Hyphae / ultrastructure*
  • Immunocompromised Host
  • Invasive Pulmonary Aspergillosis / complications
  • Invasive Pulmonary Aspergillosis / diagnosis
  • Leukemia, B-Cell / complications*
  • Leukemia, B-Cell / drug therapy
  • Lipopeptides
  • Male
  • Middle Aged
  • Neutropenia / chemically induced
  • Neutropenia / complications
  • Spleen / microbiology*
  • Spleen / ultrastructure
  • Splenectomy
  • Splenic Diseases / drug therapy
  • Splenic Diseases / etiology*
  • Splenic Diseases / microbiology
  • Splenic Diseases / pathology
  • Splenic Diseases / surgery
  • Triazoles / therapeutic use

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Triazoles
  • liposomal amphotericin B
  • posaconazole
  • Amphotericin B
  • Caspofungin